Sensei Biotherapeutics, Inc. - Common Stock (SNSE)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and concurrent $200 million private placement. The financing, together with the Company's cash on hand, is expected to support advancement of PIKTOR through key clinical milestones, including topline data readouts from both the ongoing Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201) and the planned Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101).

Issued on behalf of Oncolytics Biotech Inc.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei’s Board of Directors granted a new employee an option to purchase 166,435 shares of the Company’s common stock in connection with their employment (collectively, the “Option Award”). The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4).

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company’s common stock in connection with their employment, including a grant to Anand Parikh of an option to purchase 1,239,305 shares of the Company’s common stock in connection with his employment as Chief Operating Officer of the Company (collectively, the “Option Awards”). The Option Awards were granted as an inducement material to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4).

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipeline.

PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today announced the appointment of John Celebi, M.B.A., as chief executive officer. Mr. Celebi is a seasoned biotechnology executive with over 30 years of experience building and scaling innovative life sciences companies and has been a member of the Egle board of directors since 2024.

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) (“Sensei” or the “Company”). The investigations concern whether certain of the Sensei’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company’s business practices.

SLIEMA, Malta, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Apeiron Investment Group Ltd. (together with its affiliates “AIG”), one of the largest shareholders of Sensei Biotherapeutics, Inc. (“Sensei” or the “Company”) (NASDAQ: SNSE), which beneficially owns approximately 11.2% of the outstanding shares of Sensei’s stock, today announced that it has sent the following letter to Sensei’s Board of Directors (the “Board”).